Janssen pharmaceuticals case study

PBMCs response to TLR7 agonist

Partnership

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is a large pharmaceutical company known for developing innovative treatments. They’re responsible for research into a variety of diseases and highly recognize for their COVID-19 vaccine.

 

QurieGen collaborated with Janssen Pharmaceuticals to demonstrate the potential of QuRIEseq in studying immune responses. Janssen provided the TLR7 agonist, which activates immune cells. QuRIEseq was optimized for primary cells (PBMCs) and used it to track gene expression changes in individual cells over time upon TLR7 agonist stimulation. This allowed them to identify how different cell types within PBMCs respond to the TLR7 agonist.

Collaboration Outcome

Specific proteins are activated in different cell types over time upon TLR7 agonist stimulation.

Single-cell response data allowed researchers to map individual cells to specific cell types.

QuRIE-seq works with primary cells, which is a challenge due to their small size and low mRNA content.

In-Depth Collaboration

In this study, we demonstrated the potential of QuRIEseq for analyzing heterogeneous populations of primary cells, focusing on the entire population of peripheral blood mononuclear cells (PBMCs). Treatment with a stimulus revealed time-dependent, cell-(sub)type-specific changes in both the transcriptome and proteome landscapes.

DOWNLOAD THE FULL CASE STUDY

Scroll to Top